Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

The role of JAK inhibitors in multiple myeloma.

Ghermezi M, Spektor TM, Berenson JR.

Clin Adv Hematol Oncol. 2019 Sep;17(9):500-505.

PMID:
31549971
2.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR.

Target Oncol. 2019 Oct;14(5):551-561. doi: 10.1007/s11523-019-00666-0.

PMID:
31473933
3.

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.

Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, Cao J, Hekmati T, Zahab B, Nosrati JD, Wen M, Wang CS, Tang G, Xu N, Spektor TM, Berenson JR.

Br J Haematol. 2019 Aug 18. doi: 10.1111/bjh.16158. [Epub ahead of print]

PMID:
31423579
4.

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.

Shah J, Usmani S, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):570-578.e1. doi: 10.1016/j.clml.2019.05.017. Epub 2019 May 29.

PMID:
31326409
5.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.

Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Ghermezi M, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg R, Yashar MA, Wang CS, Tang GY, Spektor TM, Berenson JR.

Leuk Res. 2019 Jun;81:62-66. doi: 10.1016/j.leukres.2019.04.008. Epub 2019 Apr 18.

PMID:
31035033
6.

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.

Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, Schlossberg RE, Vidisheva A, Tanenbaum EJ, Hekmati T, Zahab B, Wang C, Tang G, Chen H, Berenson JR.

Ann Hematol. 2019 Mar;98(3):691-703. doi: 10.1007/s00277-019-03595-0. Epub 2019 Jan 11.

PMID:
30635766
7.

Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.

Rahbari KJ, Nosrati JD, Spektor TM, Berenson JR.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18. No abstract available.

PMID:
30033209
8.

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK.

Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

PMID:
29866475
9.

Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.

Gross Z, Rahbari A, Wirtschafter E, Spektor TM, Udd KA, Bujarski S, Ghermezi M, Nosrati JD, Vidisheva A, Eades B, Cecchi G, Maluso T, Swift R, Berenson JR.

Eur J Haematol. 2018 Jun;100(6):621-623. doi: 10.1111/ejh.13058. Epub 2018 Apr 25.

PMID:
29524348
10.

Monitoring multiple myeloma.

Udd KA, Spektor TM, Berenson JR.

Clin Adv Hematol Oncol. 2017 Dec;15(12):951-961.

PMID:
29315287
11.

The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.

Sanchez E, Smith EJ, Yashar MA, Patil S, Li M, Porter AL, Tanenbaum EJ, Schlossberg RE, Soof CM, Hekmati T, Tang G, Wang CS, Chen H, Berenson JR.

Target Oncol. 2018 Feb;13(1):39-47. doi: 10.1007/s11523-017-0538-x. Review.

PMID:
29230672
12.

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.

Cohen A, Spektor TM, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Maluso T, Swift RA, Vescio R, Berenson JR.

Br J Haematol. 2018 Jan;180(1):60-70. doi: 10.1111/bjh.14992. Epub 2017 Nov 21.

PMID:
29164606
13.

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).

Boccia RV, Bessudo A, Agajanian R, Conkling P, Harb W, Yang H, Pinchasik D, Kimball AS, Berenson JR.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):433-437. doi: 10.1016/j.clml.2017.05.009. Epub 2017 May 10.

14.

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR.

Support Care Cancer. 2017 Oct;25(10):3217-3224. doi: 10.1007/s00520-017-3732-6. Epub 2017 Apr 28.

PMID:
28455546
15.

Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).

Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, Berenson JR.

Leuk Res. 2017 Jun;57:45-54. doi: 10.1016/j.leukres.2017.03.002. Epub 2017 Mar 6. Review.

PMID:
28288323
16.

Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.

Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR.

Mol Cancer Res. 2017 May;15(5):598-609. doi: 10.1158/1541-7786.MCR-16-0293. Epub 2017 Jan 25.

17.

Circulating proteasomes: circling myeloma with a new potential biomarker.

Spektor TM, Berenson JR.

Leuk Lymphoma. 2017 Mar;58(3):513-515. doi: 10.1080/10428194.2016.1274981. Epub 2017 Jan 16. No abstract available.

PMID:
28093000
18.

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.

Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang CS, Swift RA, Chen H, Berenson JR.

Haematologica. 2017 Apr;102(4):785-795. doi: 10.3324/haematol.2016.150896. Epub 2016 Dec 29.

19.

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.

Ann Hematol. 2017 Mar;96(3):449-459. doi: 10.1007/s00277-016-2889-2. Epub 2016 Dec 8.

PMID:
27933373
20.

Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.

Ann Hematol. 2017 Mar;96(3):441-448. doi: 10.1007/s00277-016-2888-3. Epub 2016 Dec 2.

PMID:
27913860
21.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG.

Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12.

22.

Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.

Harutyunyan NM, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, Berenson JR.

Br J Haematol. 2016 Jul;174(1):81-7. doi: 10.1111/bjh.14026. Epub 2016 Mar 27.

PMID:
27017948
23.

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.

Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang CS, Chen H, Berenson JR.

Clin Cancer Res. 2016 Jul 1;22(13):3383-97. doi: 10.1158/1078-0432.CCR-15-2224. Epub 2016 Mar 9.

24.

Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.

Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, Treisman J, Masri M, Berenson JR.

Support Care Cancer. 2016 Jul;24(7):3105-10. doi: 10.1007/s00520-016-3126-1. Epub 2016 Feb 23.

PMID:
26902977
25.

Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.

Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR.

Eur J Haematol. 2016 Nov;97(5):439-444. doi: 10.1111/ejh.12748. Epub 2016 Mar 7.

PMID:
26872804
26.

Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.

Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML.

J Natl Cancer Inst. 2015 Nov 18;108(3). pii: djv342. doi: 10.1093/jnci/djv342. Print 2016 Mar. Review.

27.

Counterpoints: Do patients with multiple myeloma need maintenance treatment? Yes, but the proper candidates and schedule must be determined.

Berenson JR, Andreu-Vieyra C.

Clin Adv Hematol Oncol. 2015 Mar;13(3):163-6. No abstract available.

PMID:
26352423
28.

The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

Andreu-Vieyra CV, Berenson JR.

Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614. Review.

29.

A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.

Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Schlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, Vescio R.

Support Care Cancer. 2015 Jun;23(6):1503-12. doi: 10.1007/s00520-014-2486-7. Epub 2014 Nov 5.

PMID:
25370889
30.

Bone-targeted therapies for cancer patients and bone cell biology: where do we stand?

Berenson JR.

Curr Opin Support Palliat Care. 2014 Dec;8(4):405-6. doi: 10.1097/SPC.0000000000000104. No abstract available.

PMID:
25319276
31.

Carfilzomib in multiple myeloma.

Andreu-Vieyra C, Berenson JR.

Expert Opin Biol Ther. 2014 Nov;14(11):1685-99. doi: 10.1517/14712598.2014.953050. Epub 2014 Aug 29. Review.

PMID:
25170966
32.

More treatment is not always better.

Berenson JR.

Clin Adv Hematol Oncol. 2014 May;12(5):319-21. No abstract available.

PMID:
25134175
33.

Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.

Huerta-Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera-Muñoz M, Rivera-Pazos C, Maldonado-Valenzuela A, Valencia-Hipolito A, Vega MI, Chen H, Berenson JR, Bonavida B.

Int J Oncol. 2014 Sep;45(3):1184-92. doi: 10.3892/ijo.2014.2511. Epub 2014 Jun 20.

PMID:
24970600
34.

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R.

Blood. 2014 Aug 14;124(7):1047-55. doi: 10.1182/blood-2014-01-548941. Epub 2014 Jun 5.

35.

Multiple myeloma: treatment updates.

Berenson JR.

Clin Adv Hematol Oncol. 2013 Nov;11(11):744-5. Review. No abstract available.

PMID:
24896549
36.

In vivo models of multiple myeloma (MM).

Sanchez E, Chen H, Berenson JR.

Biochem Pharmacol. 2014 Jun 1;89(3):313-20. doi: 10.1016/j.bcp.2014.03.013. Epub 2014 Apr 1.

PMID:
24704250
37.

Cryoglobulinemia: better treatments with brighter outcomes.

Berenson JR.

Oncology (Williston Park). 2013 Nov;27(11):1125-6, 1128. No abstract available.

38.

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.

Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Y, Swift RA, Vescio RA.

Leukemia. 2014 Jul;28(7):1529-36. doi: 10.1038/leu.2014.27. Epub 2014 Jan 16.

PMID:
24429497
39.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M.

Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11.

40.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, Ghazal HH, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, Vescio R.

Ann Hematol. 2014 Jan;93(1):89-98. doi: 10.1007/s00277-013-1910-2. Epub 2013 Oct 18.

PMID:
24135804
41.

Updates in the treatment of multiple myeloma.

Berenson JR.

Clin Adv Hematol Oncol. 2012 Oct;10(10):667-9. No abstract available.

PMID:
23187773
42.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D.

Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15.

PMID:
23150919
43.

CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.

Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR.

Leuk Res. 2012 Nov;36(11):1422-7. doi: 10.1016/j.leukres.2012.07.018. Epub 2012 Aug 17.

PMID:
22906694
44.

Multiple myeloma: improved outcomes with new therapeutic approaches.

Eshaghian S, Berenson JR.

Curr Opin Support Palliat Care. 2012 Sep;6(3):330-6. doi: 10.1097/SPC.0b013e3283565c56. Review.

PMID:
22871979
45.

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.

Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR.

Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18.

PMID:
22804669
46.

Is vertebral augmentation the right choice for cancer patients with painful vertebral compression fractures?

Papanastassiou ID, Aghayev K, Berenson JR, Schmidt MH, Vrionis FD.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):715-9.

PMID:
22679116
47.

Anti-myeloma effects of the novel anthracycline derivative INNO-206.

Sanchez E, Li M, Wang C, Nichols CM, Li J, Chen H, Berenson JR.

Clin Cancer Res. 2012 Jul 15;18(14):3856-67. doi: 10.1158/1078-0432.CCR-11-3130. Epub 2012 May 22.

48.

Comparing effects of kyphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies.

Papanastassiou ID, Phillips FM, Van Meirhaeghe J, Berenson JR, Andersson GB, Chung G, Small BJ, Aghayev K, Vrionis FD.

Eur Spine J. 2012 Sep;21(9):1826-43. Epub 2012 Apr 29. Review.

49.

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.

Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Y, Vescio R, Swift RA.

Leukemia. 2012 Jul;26(7):1675-80. doi: 10.1038/leu.2012.51. Epub 2012 Feb 22.

PMID:
22354206
50.

The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.

Berenson JR.

Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):2-4. doi: 10.1016/j.clml.2011.03.025. Epub 2011 May 4. No abstract available.

PMID:
22130220

Supplemental Content

Loading ...
Support Center